These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 26522958)

  • 1. Genetic deletion of Rhes or pharmacological blockade of mTORC1 prevent striato-nigral neurons activation in levodopa-induced dyskinesia.
    Brugnoli A; Napolitano F; Usiello A; Morari M
    Neurobiol Dis; 2016 Jan; 85():155-163. PubMed ID: 26522958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats.
    Brugnoli A; Pisanò CA; Morari M
    Neurobiol Dis; 2020 Oct; 144():105044. PubMed ID: 32798726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels.
    Mela F; Marti M; Bido S; Cenci MA; Morari M
    Neurobiol Dis; 2012 Jan; 45(1):573-82. PubMed ID: 22001605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
    Paolone G; Brugnoli A; Arcuri L; Mercatelli D; Morari M
    Mov Disord; 2015 Nov; 30(13):1728-38. PubMed ID: 26207892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rhes, a striatal-enriched small G protein, mediates mTOR signaling and L-DOPA-induced dyskinesia.
    Subramaniam S; Napolitano F; Mealer RG; Kim S; Errico F; Barrow R; Shahani N; Tyagi R; Snyder SH; Usiello A
    Nat Neurosci; 2011 Dec; 15(2):191-3. PubMed ID: 22179112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels.
    Bido S; Marti M; Morari M
    J Neurochem; 2011 Sep; 118(6):1043-55. PubMed ID: 21740438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
    Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
    J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats.
    Mabrouk OS; Mela F; Calcagno M; Budri M; Viaro R; Dekundy A; Parsons CG; Auberson YP; Morari M
    ACS Chem Neurosci; 2013 May; 4(5):808-16. PubMed ID: 23611155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of the Protein Ras Homolog Enriched in the Striatum, Rhes, in Dopaminergic Neurons' Degeneration: Link to Parkinson's Disease.
    Serra M; Pinna A; Costa G; Usiello A; Pasqualetti M; Avallone L; Morelli M; Napolitano F
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34070217
    [No Abstract]   [Full Text] [Related]  

  • 10. mTORC1 signaling in Parkinson's disease and L-DOPA-induced dyskinesia: A sensitized matter.
    Santini E; Valjent E; Fisone G
    Cell Cycle; 2010 Jul; 9(14):2713-8. PubMed ID: 20581466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenosine A1 receptor stimulation reduces D1 receptor-mediated GABAergic transmission from striato-nigral terminals and attenuates l-DOPA-induced dyskinesia in dopamine-denervated mice.
    Mango D; Bonito-Oliva A; Ledonne A; Cappellacci L; Petrelli R; Nisticò R; Berretta N; Fisone G; Mercuri NB
    Exp Neurol; 2014 Nov; 261():733-43. PubMed ID: 25173217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
    Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias.
    Marti M; Rodi D; Li Q; Guerrini R; Fasano S; Morella I; Tozzi A; Brambilla R; Calabresi P; Simonato M; Bezard E; Morari M
    J Neurosci; 2012 Nov; 32(46):16106-19. PubMed ID: 23152595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Striatal mRNA expression patterns underlying peak dose L-DOPA-induced dyskinesia in the 6-OHDA hemiparkinsonian rat.
    Smith LM; Parr-Brownlie LC; Duncan EJ; Black MA; Gemmell NJ; Dearden PK; Reynolds JN
    Neuroscience; 2016 Jun; 324():238-51. PubMed ID: 26968766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA.
    Marti M; Trapella C; Morari M
    J Neurochem; 2008 Dec; 107(6):1683-96. PubMed ID: 19014386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of glutamic acid decarboxylase (Gad67) in striatal neurons expressing the Drdr1a dopamine receptor prevents L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned mice.
    Zhang K; Chammas C; Soghomonian JJ
    Neuroscience; 2015 Sep; 303():586-94. PubMed ID: 26188284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
    Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
    J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model.
    Di Monte DA; McCormack A; Petzinger G; Janson AM; Quik M; Langston WJ
    Mov Disord; 2000 May; 15(3):459-66. PubMed ID: 10830409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia.
    Santini E; Heiman M; Greengard P; Valjent E; Fisone G
    Sci Signal; 2009 Jul; 2(80):ra36. PubMed ID: 19622833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling.
    Rylander D; Recchia A; Mela F; Dekundy A; Danysz W; Cenci MA
    J Pharmacol Exp Ther; 2009 Jul; 330(1):227-35. PubMed ID: 19357321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.